The interest in FGF pathway inhibitors relies also in the possibility to overcome resistance to VEGF inhibition that may arise after long term use of these drugs or could be intrinsic in tumor expressing FGF2 (67–69). This evidence concerns the gene FGF2 and neoplasm.